SCHEMBL20129062

SCHEMBL20129062

CCCCCOCCCCCOC1CCCCO1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SPHK2 Q9NRA0 1/20 0.40
SPHK1 Q9NYA1 1/20 0.40
THRB P10828 1/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
EPHX1 P07099 1/20 0.39
KDM4C Q9H3R0 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GBA1 P04062 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
PTAFR P25105 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20365467 0.97 MEN1 (0.46) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL5652692 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL14971389 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL4478966 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL9841873 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL10066970 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL15686649 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL3230862 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL3103625 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2
SCHEMBL12723040 0.96 MEN1 (0.50) MEN1KMT2AALDH1A1TDP1SPHK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN MEN1 1944/4885KMT2A 1250/4885ALDH1A1 3804/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885ALDH1A1 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.